Given a paragraph and a claim, classify it this way: If the claim contradicts the evidence present in the paragraph, classify the claim as '0'. If the claim has multiple supporting *AND* contradicting evidences, classify the claim as '1'. If the claim has supporting evidence and the paragraph is in overall favor of the claim, then classify the claim as '2'.
--------
Question: Paragraph: P&G, with roughly $68 billion in annual revenue, said it has invested millions in creating and testing refills for detergents over the years and is now trying to push in to mainstream beauty and body care refills – which are virtually  unheard of. It recently began offering some Olay face-cream jars with refill pouches on Olay.com, telling Reuters it has plans to expand the sales of the pouches in Europe early next year. “We’re learning on our legs so I don’t know that we’re in a position to say, ‘Hey, here’s the magic to selling refills,’” P&G spokesman Damon Jones said. Beauty products retailer The Body Shop, owned by Brazil’s Natura Cosmeticos SA NATU3.SA, says it plans to roll out “refill stations” in its stores globally next year, allowing shoppers to buy reusable metal containers to fill with Body Shop shower gels or creams. The company had offered refills at its stores in the early 1990s, but discontinued them in 2003, citing a lack of consumer demand. Unilever, which has set targets for reducing and recycling plastic by 2025, in October announced the planned launch of “refill sticks” of deodorants under its Dove line of personal care products on Loopstore.com. The website, operated by recycling company TerraCycle, offers consumers the chance to buy some household products in ultra-durable packaging with refills delivered to their doors, milkman-style. Across the consumer goods industry, results for refillable products have been mixed so far as many shoppers are far too set in their ways to be easily weaned from living in a throwaway culture. While refills are less expensive to purchase - generally priced at 20% to 30% less per item than the containers they are aimed to replenish, according to Unilever - shoppers have so far, for the most part, failed to snap them up, the companies said. SC Johnson & Son Inc, marketer of Windex and Pledge, said refills and concentrates so far have not played well with either Americans or Europeans over the decade they have been offered, with unit sales of such products pretty much flat. It pulled concentrated refills for Shout stain remover off the shelves because they were not selling very well. In 2010, Unilever put 20-liter tanks to dispense detergents in Walmart Inc’s (WMT.N) British supermarket chain Asda, and provided flexible pouches for customers to refill. But with leaky machines, safety and maintenance problems and the high costs of upkeep, Unilever said the tests fell short of expectations. Asda was also unhappy because the tanks occupied a lot of space. “None of them sell very well – it is a convenience issue,” SC Johnson CEO Fisk Johnson told Reuters. Johnson said some people find it painstaking to wash and refill bottles themselves while others worry that smaller bottles filled with concentrates are less “bang-for-your-buck” than the larger ones they have used for years. Still, the privately held company said it was expanding its refill offerings this year to address concerns surrounding plastic waste and is also testing refill stations for cleaning products with UK retailer Waitrose, owned by Britain’s John Lewis [JLPLC.UL]. The Waitrose tests are showing the first signs of progress in refill sales, Johnson said, and the company is now thinking of expanding the project. Even if consumers are comfortable using refills for some household goods, it is more complicated to sell them for products like Pantene shampoo and Olay creams, P&G spokesman Jones said. For instance, with beauty products, the look and feel of packaging is a big factor in creating and maintaining customer loyalty, while delivering an environmental benefit, he said. Some shoppers say they want to buy refillable products, but that the offerings are not available at many stores. Earlier this year, dozens of consumers took to social media to urge The Body Shop to bring back its refill counters. “Refill, refill, refill!” Twitter user @JaiChipperfield said on July 22, joining a thread in which several other shoppers demanded the return of refills. “Seems to me that judging by these comments your customers want to see the return of refills,” @JaiChipperfield added. “Me too, it would be brilliant to see that return.”  The Body Shop eventually responded to those pleas. “Now with the renewed focus on sustainability, we believe it is the right time to return with it,” Body Shop spokeswoman Lucy Muircroft told Reuters this week. Claim: Procter & Gamble, rivals take refills into beauty aisle.

Answer: 2


Question: Paragraph: "A  post about COVID-19 is being shared in a new format on Facebook. In an audio message that a reader sent us on March 23, a woman with a British accent lists 10 ways that people can avoid being infected with the coronavirus. The message claims to be based on research from Chinese scientists. ""It was sent to me by a colleague who has a friend that works at Dr. Negrin, which is the main hospital on our island,"" says the woman on the audio message. ""It’s obviously in Spanish, so I’m just going to read it and translate it for you."" University Hospital of Gran Canaria Dr. Negrin is located in the city of Las Palmas on Gran Canaria, one of Spain’s Canary Islands. The island chain’s tourism industry has been hard-hit by the COVID-19 pandemic. Here’s some of the questionable medical advice in the audio message that caught our eye: If some of those claims sound familiar, it’s because many of them have been circulating on social media in some form since January, when the World Health Organization addressed a slew of COVID-19 rumors on Twitter. We’ve also debunked several bogus coronavirus prevention and treatment methods. But this audio message was new to us, so we decided to check out each of the five claims. All of them either lack evidence or have been debunked by public health officials. While health experts recommend drinking water regularly to stay healthy, there is no evidence that sipping some every 20 minutes can help prevent coronavirus infection. The primary way the virus spreads is through close contact with infected people and respiratory droplets, according to the Centers for Disease Control and Prevention. When someone with the coronavirus coughs or sneezes, their germs land on surfaces around them. The virus then infects people who touch those surfaces and then their eyes, nose or mouth. So to prevent contracting the coronavirus, the CDC advises people to avoid touching their face as much as possible. Other ways to prevent infection include washing your hands with soap and water, covering your coughs and sneezes with a tissue and regularly sanitizing the surfaces in your home or at your workstation. As of now, there is no specific treatment for the virus. In a tweet published Feb. 7, the WHO said it does not advise people to drink water as a way to avoid coronavirus infection. While air-drying your clothes may save you some money on your electricity bill, there is no evidence it will kill the coronavirus. We’ve rated similar claims . There is ample evidence that viruses, including human coronaviruses, don’t like heat. Influenza, for example, thrives in dry, cold weather, which is one reason the flu season typically spans from fall to spring. And high-intensity UV light can kill viruses. Here are 4 real ways to protect yourself But that doesn’t mean sun exposure kills the coronavirus. Experts told us natural sunlight doesn’t provide the UV intensity needed to kill the virus, and the WHO says on its website that COVID-19 can be transmitted in all climates, ""including areas with hot and humid weather."" Neither the WHO nor the CDC lists sunlight exposure as a method to kill the coronavirus. In fact, the WHO has debunked the claim, saying ""there is no evidence that sunlight kills the new coronavirus."" Public health officials say washing your hands is one of the primary ways to prevent COVID-19 infection. But if you’re healthy and in self-isolation, there is probably little reason to lather up so frequently. The CDC recommends washing your hands with soap and water for at least 20 seconds at a time — ""especially after you have been in a public place, or after blowing your nose, coughing, or sneezing."" On its website, UNICEF lists a few more examples of when people should wash their hands: ""after touching surfaces outside the home, including money; before, during and after caring for a sick person; and before and after eating."" So if you’re doing any of those things every 20 minutes, you may want to wash your hands. This claim is baseless. As we’ve covered before, there is evidence that human coronaviruses don’t like heat. But just as there’s no scientific proof that hot things prevent COVID-19, there’s no proof that cold things make you more susceptible. This claim is similar to one made in a fake UNICEF handout that circulated on Facebook in early March. It said people should ""stay away from ice cream and eating cold"" to avoid contracting COVID-19. In a statement, UNICEF debunked that claim. On its website, the WHO did, too. ""There is no scientific evidence that eating hygienically made frozen food and ice-cream spreads the new coronavirus,"" the organization says. There’s no evidence to support this. An article published in the New England Journal of Medicine on March 17 tested how long the coronavirus, formally called SARS-CoV-2, lived on five different surfaces: aerosols, plastic, stainless steel, copper and cardboard. ""SARS-CoV-2 remained viable in aerosols throughout the duration of our experiment (3 hours),"" the authors wrote. ""SARS-CoV-2 was more stable on plastic and stainless steel than on copper and cardboard."" On cardboard, they could not detect any after 24 hours. The coronavirus lives the longest on plastic and stainless steel — up to three days. That’s far from nine days, as the audio message claimed. And while the journal article hasn’t been peer-reviewed, its findings are similar to those of other researchers. An article published in the Journal of Hospital Infection in March reviewed what other scientists have found about the surface viability of various coronaviruses that infect humans, such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), which are both similar to COVID-19. The authors wrote that scientists found some of these viruses could live for up to five days on steel, and eight hours on aluminum. Another study they cited found a SARS virus strain remaining viable for up to five days on an unspecified metal. The article did find that one strain of SARS could live for up to nine days on plastic surfaces. But two other strains of the virus remained viable for only five days or less, and MERS could live for only up to 48 hours at a certain temperature. More recently, a March 23 report from the CDC said novel coronavirus RNA was found on surfaces on the Diamond Princess cruise ship 17 days after passengers disembarked. That finding raised questions about whether the coronavirus can last longer on some surfaces than previously thought, but researchers have noted that viral RNA doesn’t necessarily mean live virus was present. A chain audio message on Facebook Messenger lists 10 ways to prevent infection from COVID-19. We fact-checked five and found them inaccurate. First, there is no evidence that sipping water every 20 minutes can help prevent coronavirus infection. There is also no evidence that exposing your clothing to the sun will kill the coronavirus. Health officials recommend that people avoid touching their face and wash their hands for at least 20 seconds at a time —  not every 20 minutes, as the message claims. There’s also no evidence that consuming cold things makes you more susceptible to the virus. Finally, while the science is far from settled, there’s no proof that the coronavirus can live for up to nine days on metallic surfaces. The best available evidence suggests that it can remain viable on stainless steel for up to three days. If you receive a chain message that you want us to fact-check, send a screenshot to [email protected] or forward it to us on Facebook." Claim: An audio message lists five ways people can prevent the novel coronavirus.

Answer: 0


Question: Paragraph: Although Pfizer continues to test the drug, called dacomitinib, in another Phase III study, hopes for its success have now largely faded, according to ISI Group analyst Mark Schoenebaum. “We believe consensus expectations (for the drug) will be close to zero given today’s readout” of unsuccessful trial results, Schoenebaum said in a research note. In one of the failed trials, called ARCHER 1009, patients given Pfizer’s once-daily pill did not show improved survival without the cancer worsening, compared with Roche Holding AG’s widely used Tarceva (erlotinib). Tarceva is the current standard of care in patients with mutated forms of a protein called Epidermal Growth Factor Receptor (EGFR). The protein plays a role in normal regulation of cell growth, but when mutated is believed to cause cells to proliferate and thereby help spur various types of cancer. Dacomitinib is designed to block several types of Epidermal Growth Factor receptors, while Tarceva and similar treatments for lung cancer target only one type of receptor. Cowen and Co had forecast annual sales of $500 million by 2020 for dacomitinib, if it were approved for lung cancer. That would make it a moderate-sized product for Pfizer, the largest U.S. drugmaker, which has annual revenue of $50 billion. Schoenebaum said there has been little investor interest in the drug and that Wall Street had expected it to generate annual sales of only $300 million by 2018. The second failed trial, named BR.26, involved patients that previously had failed to benefit from chemotherapy as well as from treatment with an EGFR inhibitor. Overall survival of patients taking the Pfizer drug was not prolonged in the study, compared with patients given a placebo. Pfizer said adverse events seen with dacomitinib were consistent with those seen in smaller earlier studies. In the meantime, Pfizer said dacomitinib is also being tested in a third late-stage trial, called ARCHER 1050, among patients with advanced non-small cell lung cancer who have not received prior treatment. The study will compare dacomitinib with Iressa (gefitinib), an EGFR inhibitor sold by AstraZeneca Plc. Results from that study are expected in 2015. Pfizer shares were little changed in morning trading on the New York Stock Exchange. Claim: Pfizer lung cancer drug fails in two large studies.

Answer:
2